9-nitrocamptothecin inhibits tumor necrosis factor-mediated activation of human immunodeficiency virus type 1 and enhances apoptosis in a latently infected T cell clone

AIDS Research and Human Retroviruses

Volumn 14, Issue 1, 1998, Pages 39-49

  Moulton, Stacy ^a   Pantazis, Panayotis ^b   Epstein, Jay S ^a   Sadaie, M Reza ^a,c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b St Joseph's Medical Center Houston   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; RUBITECAN; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE; VIREMIA; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EID: 0031963961     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.39     Document Type: Article

References (68)

1. Coombs RW, Collier AC, Allain JP, et al.: Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989;321: 1626-1631.
2. Ho DD, Moudgil T, and Alam M: Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989;321:1621-1625.
3. Haynes BF, Pantaleo G, and Fauci AS: Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996;271:324-328.
4. Bukrinsky MI, Stanwick TL, Dempsey MP, and Stevenson M: Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 1991;254:423-427.
5. Patterson BK, Till M, Otto P, et al.: Detection of HIV-1 DNA and messenger RNA in individual cells by PCR-driven in situ hybridization and flow cytometry. Science 1993;260:976-979.
6. Embretson J, Zupancic M, Beneke J, et al.: Analysis of human immunodeficiency virus-infected tissues by amplification and in situ hybridization reveals latent and permissive infections at single-cell resolution. Proc Natl Acad Sci USA 1993;90:357-361.
7. Fauci AS: The human immunodeficiency virus: Infectivity and mechanisms of pathogenesis. Science 1988;239:617-622.
8. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, and Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.
9. Saksela K, Muchmore E, Girard M, Fultz P, and Baltimore D: High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees. J Virol 1993;67:7423-7427.
10. Folks TM, Clouse KA, Justement J, et al.: Tumor necrosis factor-α induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 1989; 86:2365-2368.
11. Pomerantz RJ, Trono D, Feinberg MB, and Baltimore D: Cells non-productively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency. Cell 1990;61:1271-1276.
12. Golub EI, Li G, and Volsky DJ: Induction of dormant HIV-1 by sodium butyrate: Involvement of the TATA box in the activation of the HIV-1 promoter. AIDS 1991;5:663-668.
13. Popik W and Pitha PM: Role of tumor necrosis factor alpha in activation and replication of the tar-defective human immunodeficiency virus type 1. J Virol 1993;67:1094-1099.
14. Sadaie MR and Hager GL: Induction of developmentally programmed cell death and activation of HIV by sodium butyrate. Virology 1994;202:513-518.
15. Fauci AS: Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science 1993;262:1011-1018.
16. Kalinkovich A, Engelmann H, Harpaz N, et al.: Elevated serum levels of soluble tumor necrosis factor receptors in patients with HIV infection. Clin Exp Immunol 1992;89:351-355.
17. Kalinkovich A, Geleziunas R, Kemper O, et al.: Increased soluble tumor necrosis factor receptor expression and release by human immunodeficiency virus type 1 infection. J Interferon Cytokine Res 1995;15:749-757.
18. Aukrust P, Liabakk NB, Muller F, Lien E, Espevik T, and Froland SS: Serum levels of tumor necrosis factor-α (TNF-α) and soluble TNF receptors in human immunodeficiency virus type 1 infection-correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994;169:420-424.
19. Zangerle R, Gallati H, Sarcletti M, et al.: Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation. J AIDS 1994;7:79-85.
20. Rosenberg ZF and Fauci AS: Minireview: Induction of expression of HIV in latently or chronically infected cells. AIDS Res Hum Retroviruses 1989;5:1-4.
21. Riggs MG, Whittaker RG, Neumann JR, and Ingram VM: n-Butyrate causes histone modification in HeLa and Friend erythroleukemia cells. Nature (London) 1977;268:462-464.
22. Boffa LC, Vidali G, Mann RS, Allfrey VG: Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem 1978;253:3364-3366.
23. Bresnick EH, John S, Berard DS, LeFebvre P, and Hager GL: Glucocorticoid receptor-dependent disruption of a specific nucleosome on the mouse mammary tumour virus promoter is prevented by sodium butyrate. Proc Natl Acad Sci USA 1990;87:3977-3981.
24. Osborn L, Kunkel S, and Nabel GJ: Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc Natl Acad Sci USA 1989;86:2336-2340.
25. Griffin GE, Leung K, Folks TM, Kunkel S, and Nabel GJ: Activation of HIV gene expression during monocyte differentiation by induction of NF-κB. Nature (London) 1989;339:70-73.
26. Westendorp MO, Shatrov VA, Schulze-Osthoff K, et al.: HIV-1 Tat potentiates TNF-induced NF-κB activation and cytotoxicity by altering the cellular redox state. EMBO J 1995;14:546-554.
27. Poli G, Kinter A, Justement JS, et al.; Tumor necrosis factor α functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990;87:782-785.
28. Vyakarnam A, McKeating J, Meager A, and Beverly PC: Tumor necrosis factors (α,β) virus induced by HIV-1 in peripheral blood mononuclear cells potentiate virus replication. AIDS 1990;4: 21-27.
29. Luznik L, Kraus G, Guatelli J, Richman D, and Wong-Staal F: Tat-independent replication of human immunodeficiency viruses. J Clin Invest 1995;95:328-332.
30. Bergamini A, Dini L, Capozzi M, et al.: Human immunodeficiency virus-induced cell death in cytokine-treated macrophages can be prevented by compounds that inhibit late stages of viral replication. J Infect Dis 1996;173:1367-1378.
31. Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keet RP, and Miedema F: Programmed death of T cells in HIV-1 infection. Science 1992;257:217-219.
32. Oyaizu N, McCloskey TW, Than S, and Pahwa S: Inhibition of CD4 cross-linking-induced lymphocytes apoptosis by vesnarinone as a novel immunomodulating agent: Vesnarinone inhibits Fas expression and apoptosis by blocking cytokine secretion. Blood 1996;87:2361-2368.
33. Gougeon ML, Lecoeur H, Dulioust A, et al.: Programmed cell death in peripheral lymphocytes from HIV-infected persons: Increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 1996;156:3509-3520.
34. Jardine D, Tachedjian G, Locarnini S, and Birch C: Cellular topoisomerase I activity associated with HIV-1. AIDS Res Hum Retroviruses 1993;9:1245-1250.
35. Priel E, Showalter SD, and Blair DG: Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptohecin, a topoisomerase I inhibitor. AIDS Res Hum Retroviruses 1991;7:65-72.
36. Takahashi H, Matsuda M, Kojima A, et al.: Human immunodeficiency virus type 1 reverse transcriptase: Enhancement of activity by interaction with cellular topoisomerase I. Proc Natl Acad Sci USA 1995;92:5694-5698.
37. Pantazis P: Camptothecin: A promising antiretroviral drug. J Biomed Sci 1996;3:14-19.
38. Nitiss JL: Roles of DNA topoisomerases in chromosomal replication and segregation. Adv Pharmacol 1994;29:103-134.
39. Pantazis P, Mendoza JT, Early JA, Kozielski AJ, Natelson EA, and Giovanella BC: 9-Nitro-camptothecin delays growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukemia lines in vitro. Eur J Haematol 1993;50:81-89.
40. Gupta M, Fujimori A, and Pommier Y: Eukaryotic DNA topoisomerase I. Biochim Biophys Acta 1995;1262:1-14.
41. Hwang J and Hwong CL: Cellular regulation of mammalian DNA topoisomerases. Adv Pharmacol 1994;29:167-189.
42. Drolet M, Wu H-Y, and Liu LF: Roles of DNA topoisomerases in transcription. Adv Pharmacol 1994;29:135-146.
43. Champoux JJ: Mechanism of catalysis by eukaryotic DNA topoisomerase I. Adv Pharmacol 1994;29:71-82.
44. Andersen AH, Svejstrup JQ, and Westergaard O: The DNA binding, cleavage, and religation reactions of eukaryotic topoisomerases I and II. Adv Pharmacol 1994;29:83-102.
45. Wall ME and Wani MC: Antitumor and topoisomerase I inhibition activity of camptothecin and its analogues. Econ Med Plant Res 1991;5:112-127.
46. Pommier Y, Leteurtre F, Fesen MR, et al.: Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 1994;12:530-542.
47. Pantazis P: The water-insoluble camptothecin analogues: Promising drugs for the effective treatment of haematological malignancies. Leukemia Res 1995;19:775-788.
48. Pantazis P: Preclinical studies of water-insoluble camptothecin congeners: Cytoxicity development of resistance, and combination treatments. Clin Cancer Res 1996;1:1235-1244.
49. Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS, and Pardee AB: Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Natl Acad Sci USA 1993;90:1839-1842.
50. Li CJ, Wang C, and Pardee AB: Camptothecin inhibits Tat-mediated transactivation of type I human immunodeficiency virus. J Biol Chem 1994;269:7051-7054.
51. Stehlin JS, Natelson EA, Hinz HR, et al.: Phase I clinical trial and pharmacokinetic results with oral administration of 20(S)-camptothecin. In: Camptothecins: New Anticancer Agents (Potmesil M and Pinedo H, eds.). CRC Press, Boca Raton, Florida, 1995, pp. 59-65.
52. Natelson EA, Giovanella BC, Verschraegen CF, et al.: Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann NY Acad Sci 1996;803:224-230.
53. Pantazis P, Giovanella BC, and Rothenberg HL (eds.): In: Camptothecins: From Discovery to the Patient. Ann New York Acad Sci 1996;803.
54. Nara PL, Hatch WC, Dunlop NM, et al.: Simple, rapid, quantitalive, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses 1987;3:283-302.
55. Afanasyev VN, Korol BA, Matylevich NP, Pechatnikov VA, and Umansky SR: The use of flow cytometry for the investigation of cell death. Cytometry 1993;14:603-609.
56. Oberhammer F, Wilson JW, Dive C, et al.: Apoptotic death in epithelial cells: Cleavage of DNA to 300 and/or 50 kbp fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 1993;12:3579-3684.
57. Falcieri E, Martelli AM, Bareggi R, Cataldi A, and Cocco L: The protein kinase inhibitor staurosporine induces morphological changes typical of apoptosis in MOLT-4 cells without concomitant DNA fragmentation. Biochem Biophys Res Commun 1993;193: 19-25.
58. Huschtscha LI, Jeitner TM, Andersson CE, Bartier WA, and Tattersall MH: Identification of apoptotic and necrotic human leukemic cells by flow cytometry. Exp Cell Res 1994;212:161-165.
59. Hotz MA, Gong J, Traganos F, and Darzynkiewicz Z: Flow cytometric detection of apoptosis: Comparison of the assays of in situ DNA degradation and chromatin changes. Cytometry 1994;15: 237-244.
60. Schrier RS: Internucleosomal cleavage of DNA is insufficient to conclude that cell death is apoptotic. Blood 1994;83:2005-2006.
61. Beere HM, Chresta CM, Alejo-Herberg A, et al.: Investigation of the mechanism of higher order chromatin fragmentation in drug-induced apoptosis. Mol Pharmacol 1995;47:986-996.
62. Szabó G: 50-kb chromatin fragmentation in the absence of apoptosis. Exp Cell Res 1995;221:320-325.
63. Piret B and Piette J: Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells. Nucleic Acids Res 1996;24:4242-4248.
64. Packham G, Lahti JH, Fee BE, et al.: Fas activates NF-κB and induces apoptosis in T-cell lines by signaling pathways distinct from those induced by TNF-α. Cell Death Different 1997;4:130-139.
65. Zhang JL, Sharma PL, Li CJ, et al.: Topotecan inhibits human immunodeficiency virus type I infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I. Antimicrob Agents Chemother 1997;41:977-981.
66. Cavert W, Notermans DW, Staskus K, et al.: Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997;276:960-964.
67. Kashanchi F, Melpolder JC, Epstein JS, and Sadaie MR: Rapid and sensitive detection of cell-associated HIV-1 in latently infected cell lines and in patient cells using sodium-n-butyrate induction and RT-PCR. J Med Virol 1997;52:179-189.
68. Laughlin MA, Zeichner S, Kolson D, et al: Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA. Virology 1993;196:496-505.